Lytone Debuts Breakthrough Research on Patented Probiotic Strain LT-12 for Multi-Functional Uric Acid Reduction at 19th ISPH

Share：

📰 PRESS RELEASE / PROBIOTICS & NUTRACEUTICAL INNOVATION

Dateline: GUANGZHOU, China — May 24, 2024

FOR B2B INDUSTRY PARTNERS & SCIENTIFIC RESEARCH PURPOSE ONLY (Technical Communication & Academic Reference)

Hosted by the Chinese Institute of Food Science and Technology (CIFST), the 19th International Symposium on Probiotics and Health (ISPH 2024) convened in Guangzhou from May 22 to May 24, gathering leading global experts to explore cutting-edge advances in probiotic and microbiome science. Spotlighting the next frontier of functional probiotic research, Lytone Enterprise, Inc. (TWSE: 1293) made a standout debut with its patented strain, LT-12 (Lactobacillus paracasei), unveiling compelling scientific data across uric acid management, gut microbiota health, and renal protection.

During the symposium, Wei-Ting Tseng, Chief Operating Officer of Shanghai Lytone and Chief Technology Officer of Lytone’s R&D Division, delivered a featured presentation outlining the multi-functional mechanisms behind LT-12's ability to lower uric acid levels. The presentation captured widespread interest and acclaim from international scientists, industry leaders, and clinical researchers in attendance.

"Rising global incidence of hyperuricemia and metabolic disorders has driven intense demand for natural, non-pharmacological interventions. Lytone's patented strain LT-12 offers a science-backed, multi-functional metabolic strategy to address these critical health challenges."

SECTION 01 / METABOLIC HEALTH & MULTI-FUNCTIONAL POWER

Targeting Metabolic Health: The Multi-Functional Power of Strain LT-12

Rising global incidence of hyperuricemia and metabolic disorders has driven intense demand for natural, non-pharmacological interventions. Lytone's patented strain LT-12 (Lactobacillus paracasei) addresses these challenges through a synergistic, three-pronged metabolic strategy:

Synergistic Three-Pronged Metabolic Strategy of Strain LT-12

Uric Acid Management: Inhibits key enzymatic pathways involved in purine metabolism, directly suppressing excess uric acid accumulation.
Gut Microbiota Balance: Regulates intestinal microbial ecology to enhance barrier function and reduce systemic absorption of purine precursors.
Renal Protection: Alleviates oxidative stress and inflammatory cascades within renal tissues, supporting long-term kidney function.

SECTION 02 / NUTRACEUTICAL COMMERCIALIZATION

Converting Preclinical Validation into Market-Ready Nutraceutical Solutions

By converting rigorous preclinical validation into market-ready nutraceutical formulations, Lytone continues to empower global brand owners with highly differentiated, science-backed probiotic solutions. Through its integrated R&D platform and multinational formulation capabilities, Lytone delivers comprehensive technical support and commercial innovation for brand partners expanding into the global functional health market.

Regulatory Compliance Statement: The information contained in this release regarding strain LT-12 (Lactobacillus paracasei) is intended exclusively FOR B2B INDUSTRY PARTNERS & SCIENTIFIC RESEARCH PURPOSE ONLY. It is designed for technical evaluation and scientific discussion among food, nutraceutical, and healthcare industry professionals. This material is not intended for direct consumer advertising, health diagnosis, or disease treatment claims.